DoD Reconstructive Transplant, Advanced Technology Development Award | W81XWH 21 RTRP ATDA

Opportunity Information: Apply for W81XWH 21 RTRP ATDA

The DoD Reconstructive Transplant Research Program (RTRP) Advanced Technology Development Award (FY21) is a Department of Defense funding opportunity aimed at moving strong preclinical reconstructive transplantation work closer to real-world use. The emphasis is on translation: taking promising laboratory or early-stage findings and advancing them into tangible products or actionable outputs that could ultimately be used to support patients who need reconstructive transplantation, particularly military Service Members and Veterans recovering from traumatic injury. While the research can still be preclinical in nature, the award is structured to push projects toward the next concrete development milestone, rather than supporting exploratory or purely basic science.

A central expectation of this award is a rigorous, clearly described study design that supports reproducibility and practical feasibility. Applications are expected to lay out an integrated plan that is methodologically solid and realistic to execute, with attention to how the work will stand up to scrutiny and how it will be positioned for downstream translation. When statistics apply, applicants are expected to include a statistical analysis plan and an appropriate power analysis. Importantly, the study design should not exist in isolation; it needs to connect directly to what comes next, showing that the project is deliberately engineered to prepare the product for its subsequent phase of development after the award period ends.

Military relevance and impact are also core requirements. Proposed projects must align with at least one of the program's stated FY21 focus areas (referenced in the solicitation) and must clearly explain both short-term and long-term impact. The DoD is looking for work that responds to real healthcare needs tied to traumatic injury and recovery, including needs faced by Service Members, Veterans, and, where appropriate, their family members, caregivers, and clinicians. Collaboration with military or VA investigators and clinicians is encouraged as a way to strengthen relevance and eventual adoption, but it is not mandatory. The key point is that the end product should be meaningful for military medicine and also potentially beneficial to the broader public.

Another defining feature is the required Transition Plan, submitted as a post-award plan (Attachment 9). This is meant to show how the effort will not stall after the grant ends. Applicants are expected to map out credible next steps, identify likely funding sources or resources that could carry the product forward, and describe how the technology or knowledge output could progress into the next development stage, such as preparation for clinical trials or movement toward military or civilian market delivery. A regulatory strategy is also expected when relevant, reflecting the program's focus on practical translation and real deployment considerations rather than academic proof alone.

The award is not intended for brand-new ideas without evidence. It requires preliminary data and proof of concept. Applicants must already have something substantive in hand, such as data demonstrating the utility of the proposed product or an early prototype or preliminary version of the technology. The proposal must include preliminary and/or published data relevant to reconstructive transplantation that supports the rationale for the work; this evidence can come from the team's unpublished results or from the existing scientific literature. This requirement signals that the program is designed to accelerate technologies that are already plausibly viable, not to fund initial feasibility exploration from scratch.

In terms of what can be developed, the program is relatively broad. It can support "materiel" products like drugs, biologic agents, or medical devices, as well as knowledge-based products such as technical reports or clinical practice guidelines intended to inform clinical and operational decision-making and support evidence-based updates to standard of care. Research may involve animal studies and/or human subjects research if appropriate for the development pathway. However, clinical trials are explicitly not allowed under this funding opportunity, meaning applicants need to stay short of interventional clinical trial activities while still demonstrating a clear translational trajectory.

Administratively, this FY21 opportunity is offered by the Department of Defense (Department of the Army, USAMRAA) under Funding Opportunity Number W81XWH 21 RTRP ATDA. The funding instrument types include both grants and cooperative agreements, and eligibility is described as unrestricted (open to any type of entity, subject to the solicitation's eligibility clarifications). The CFDA number listed is 12.420. The opportunity was posted in August 2021 with an original closing date in December 2021, and it anticipated making about four awards. The listing shows an award ceiling of 0, which typically indicates that the ceiling was either not specified in the summary record or was defined elsewhere in the full solicitation documents.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Reconstructive Transplant, Advanced Technology Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Aug 04, 2021.
• Applicants must submit their applications by Dec 08, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 RTRP ATDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: